Abstract
Personalised medicine has the potential to increase therapeutic effectiveness, reduce side effects and lower cost. This approach has recently taken off in oncology where different malignancies may be treated with specific drugs based on genetic biomarkers or other tumour characteristics. This type of tailored therapy could also be developed for immune-mediated inflammatory disease, for which rheumatoid arthritis (RA) may serve as a prototype. While novel treatments are able to halt or even prevent disease progression, not all RA patients respond, and stratification of patient groups is needed. The identification of biomarkers predictive of the clinical response to specific treatments in subsets of patients may soon become reality in a variety of diseases
| Translated title of the contribution | Can customized therapy become a reality? |
|---|---|
| Original language | Dutch |
| Article number | A3569 |
| Pages (from-to) | 1330-1332 |
| Number of pages | 3 |
| Journal | Nederlands Tijdschrift voor Geneeskunde |
| Volume | 155 |
| Issue number | 30-31 |
| Publication status | Published - 2011 |